Raul Calero

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

J. Montero, A. Esparís-Ogando, A. Pandiella, 2014, Oncogene.

Music Therapy in the Treatment of Dementia: A Systematic Review and Meta-Analysis

C. Pintado, R. Calero, Celia Moreno-Morales, 2020, Frontiers in Medicine.

Wnt/β-catenin pathway regulates MGMT gene expression in cancer and inhibition of Wnt signalling prevents chemoresistance

M. Kool, P. Siesjö, Emma Sandén, 2015, Nature Communications.

Sunitinib Suppress Neuroblastoma Growth through Degradation of MYCN and Inhibition of Angiogenesis

J. Johnsen, R. Calero, R. Serrano, 2014, PloS one.

An update on the biology of cancer stem cells in breast cancer

A. Ocaña, E. Poblet, J. M. García Bueno, 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

Synergistic anti-tumor effect of 17AAG with the PI3K/mTOR inhibitor NVP-BEZ235 on human melanoma.

I. Martinez-Argudo, R. Calero, R. Serrano, 2017, Cancer letters.

Active kinase profiling, genetic and pharmacological data define mTOR as an important common target in triple-negative breast cancer

J. Montero, A. Esparís-Ogando, A. Pandiella, 2014, Oncogene.

New titanocene derivative with improved stability and binding ability to albumin exhibits high anticancer activity.

I. Bravo, Pedro J. Pacheco-Liñán, I. Martinez-Argudo, 2021, Journal of inorganic biochemistry.

Novel tyrosine kinase inhibitors in the treatment of cancer.

A. Pandiella, A. Ocaña, R. Calero, 2009, Current drug targets.

Effects of epigenetic modificators in combination with small molecule inhibitors of receptor tyrosine kinases on medulloblastoma growth.

A. Ostman, Ninib Baryawno, J. Johnsen, 2014, Biochemical and biophysical research communications.